Summary of COVID-19 beta-glucans studies
Hide extended summaries
24 patient beta-glucans late treatment RCT: no change in oxygen therapy (p=1) and 12% longer hospitalization.
RCT 24 hospitalized COVID-19 patients showing potential benefit with Aureobasidium pullulans beta-glucan supplementation. While inflammatory markers (IL-6, D-dimer) initially decreased in all groups by day 15, they rebounded to abnormal levels by day 30 in the control group but continued decreasing in both beta glucan groups. The combination group showed the most consistent improvements in inflammatory markers including NLR, LCR, and LeCR ratios.
Sep 2021, Biomedicine & Pharmacotherapy, https://www.sciencedirect.com/science/article/pii/S0753332221010271, https://c19p.org/raghavan
RCT 40 COVID-19 patients showing significantly decreased IL-6 levels at day 7 with the combination of AFO-202 and N-163 beta-glucans compared to standard treatment, however there were no significant differences in clinical outcomes.
Jan 2025, Global Advances in Integrative Medicine and Health, https://journals.sagepub.com/doi/10.1177/27536130251327134, https://c19p.org/pushkala
24 patient beta-glucans late treatment RCT: no change in oxygen therapy (p=1) and 12% longer hospitalization.
RCT 24 hospitalized COVID-19 patients showing potential benefit with Aureobasidium pullulans beta-glucan supplementation. While inflammatory markers (IL-6, D-dimer) initially decreased in all groups by day 15, they rebounded to abnormal levels by day 30 in the control group but continued decreasing in both beta glucan groups. The combination group showed the most consistent improvements in inflammatory markers including NLR, LCR, and LeCR ratios.
Sep 2021, Biomedicine & Pharmacotherapy, https://www.sciencedirect.com/science/article/pii/S0753332221010271, https://c19p.org/raghavan
2. Pushkala et al., Efficient Control of IL-6, CRP and Ferritin in COVID-19 Patients With Two Variants of Beta-1,3-1,6 Glucans in Combination: An Open-Label, Prospective, Randomised Clinical Trial
40 patient beta-glucans early treatment RCT: 444% higher ventilation (p=0.2) and 444% higher ICU admission (p=0.2).RCT 40 COVID-19 patients showing significantly decreased IL-6 levels at day 7 with the combination of AFO-202 and N-163 beta-glucans compared to standard treatment, however there were no significant differences in clinical outcomes.
Jan 2025, Global Advances in Integrative Medicine and Health, https://journals.sagepub.com/doi/10.1177/27536130251327134, https://c19p.org/pushkala
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.